読み込み中
Sanofi operates as a leading global pharmaceutical enterprise, dedicated to the research, development, production, and distribution of a wide array of therapeutic solutions across the United States, Europe, and numerous international markets. The company strategically organizes its operations into three core divisions: Pharmaceuticals, Vaccines, and Consumer Healthcare. Within its Pharmaceutical segment, Sanofi delivers specialized therapies, including innovative human monoclonal antibodies, addressing complex conditions like multiple sclerosis, various neurological disorders, immunology and inflammatory diseases, oncology, rare diseases, and rare blood disorders. This segment also encompasses treatments for diabetes, cardiovascular health, and established prescription medications. Its Vaccine portfolio is extensive, offering essential immunizations such as pediatric vaccines for poliomyelitis, pertussis, and Hib, alongside influenza shots, adult boosters, meningitis vaccines, and solutions for travel and endemic diseases. The Consumer Healthcare division provides a broad spectrum of over-the-counter products, including remedies for allergies, coughs and colds, pain management, liver support, physical and mental wellness, probiotics, digestive health aids, and nutritional supplements. Additionally, it offers various personal care items like daily body lotions, anti-itch creams, moisturizing and soothing lotions, body and foot creams, and specialized powders for eczema. Sanofi maintains a robust development pipeline, with numerous pharmaceutical products and vaccines currently in various stages of research. The company actively pursues strategic alliances, exemplified by its collaboration with GlaxoSmithKline on a recombinant Covid-19 vaccine, a research partnership with Stanford University School of Medicine focused on advancing immunology and inflammation understanding, and a collaboration and license option agreement with Prellis Biologics, Inc. Founded in 1973 and headquartered in Paris, France, the company was formerly known as Sanofi-Aventis before officially changing its name to Sanofi in May 2011.
前日終値
$39.12
−$0.62 · -1.56%
時間外
$39.23
+$0.11 · +0.28%
10月13日 19:56 ET
日中の時刻はETです。市場データは遅延する場合があります。
Sanofi operates as a leading global pharmaceutical enterprise, dedicated to the research, development, production, and distribution of a wide array of therapeutic solutions across the United States, Europe, and numerous international markets. The company strategically organizes its operations into three core divisions: Pharmaceuticals, Vaccines, and Consumer Healthcare. Within its Pharmaceutical segment, Sanofi delivers specialized therapies, including innovative human monoclonal antibodies, addressing complex conditions like multiple sclerosis, various neurological disorders, immunology and inflammatory diseases, oncology, rare diseases, and rare blood disorders. This segment also encompasses treatments for diabetes, cardiovascular health, and established prescription medications. Its Vaccine portfolio is extensive, offering essential immunizations such as pediatric vaccines for poliomyelitis, pertussis, and Hib, alongside influenza shots, adult boosters, meningitis vaccines, and solutions for travel and endemic diseases. The Consumer Healthcare division provides a broad spectrum of over-the-counter products, including remedies for allergies, coughs and colds, pain management, liver support, physical and mental wellness, probiotics, digestive health aids, and nutritional supplements. Additionally, it offers various personal care items like daily body lotions, anti-itch creams, moisturizing and soothing lotions, body and foot creams, and specialized powders for eczema. Sanofi maintains a robust development pipeline, with numerous pharmaceutical products and vaccines currently in various stages of research. The company actively pursues strategic alliances, exemplified by its collaboration with GlaxoSmithKline on a recombinant Covid-19 vaccine, a research partnership with Stanford University School of Medicine focused on advancing immunology and inflammation understanding, and a collaboration and license option agreement with Prellis Biologics, Inc. Founded in 1973 and headquartered in Paris, France, the company was formerly known as Sanofi-Aventis before officially changing its name to Sanofi in May 2011.
日中レンジ
現在 $39.12
52週レンジ
現在 $39.12
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
買い
バリュエーション
79
割安
センチメント
62
強気
リスク
26
中程度のリスク
モメンタム
38
弱含み
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Sanofi operates as a leading global pharmaceutical enterprise, dedicated to the research, development, production, and distribution of a wide array of therapeutic solutions across the United States, Europe, and numerous international markets. The company strategically organizes its operations into three core divisions: Pharmaceuticals, Vaccines, and Consumer Healthcare. Within its Pharmaceutical segment, Sanofi delivers specialized therapies, including innovative human monoclonal antibodies, addressing complex conditions like multiple sclerosis, various neurological disorders, immunology and inflammatory diseases, oncology, rare diseases, and rare blood disorders. This segment also encompasses treatments for diabetes, cardiovascular health, and established prescription medications. Its Vaccine portfolio is extensive, offering essential immunizations such as pediatric vaccines for poliomyelitis, pertussis, and Hib, alongside influenza shots, adult boosters, meningitis vaccines, and solutions for travel and endemic diseases. The Consumer Healthcare division provides a broad spectrum of over-the-counter products, including remedies for allergies, coughs and colds, pain management, liver support, physical and mental wellness, probiotics, digestive health aids, and nutritional supplements. Additionally, it offers various personal care items like daily body lotions, anti-itch creams, moisturizing and soothing lotions, body and foot creams, and specialized powders for eczema. Sanofi maintains a robust development pipeline, with numerous pharmaceutical products and vaccines currently in various stages of research. The company actively pursues strategic alliances, exemplified by its collaboration with GlaxoSmithKline on a recombinant Covid-19 vaccine, a research partnership with Stanford University School of Medicine focused on advancing immunology and inflammation understanding, and a collaboration and license option agreement with Prellis Biologics, Inc. Founded in 1973 and headquartered in Paris, France, the company was formerly known as Sanofi-Aventis before officially changing its name to Sanofi in May 2011.
日中レンジ
現在 $39.12
52週レンジ
現在 $39.12
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（EUR） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 467.16億 EUR | 442.86億 EUR | 416.18億 EUR | 405.61億 EUR | 391.75億 EUR |
| 売上原価 | 130.49億 EUR | 132.05億 EUR | 126.28億 EUR | 118.82億 EUR | 122.55億 EUR |
| 粗利益 | 336.67億 EUR | 310.81億 EUR | 289.9億 EUR | 286.79億 EUR | 269.2億 EUR |
| 研究開発 | 78.42億 EUR | 73.94億 EUR | 65.07億 EUR | 65.01億 EUR | 56.92億 EUR |
| 販売・一般管理 | 102.42億 EUR | 91.83億 EUR | 89.33億 EUR | 87.39億 EUR | 95.55億 EUR |
| 営業費用 | 240.7億 EUR | 238.29億 EUR | 220.3億 EUR | 185.17億 EUR | 187.94億 EUR |
| 受取利息 | 3.31億 EUR | 4.58億 EUR | 5.31億 EUR | 1.69億 EUR | 312.7万 EUR |
| 支払利息 | 6.26億 EUR | 6.23億 EUR | 5.13億 EUR | 3.85億 EUR | 3.77億 EUR |
| 減価償却費と償却費 | 56.78億 EUR | 35.86億 EUR | 44.29億 EUR | 31.08億 EUR | 33.51億 EUR |
| 営業利益 | 95.97億 EUR | 72.52億 EUR | 69.6億 EUR | 101.62億 EUR | 81.26億 EUR |
| 純利益 | 78.13億 EUR | 55.6億 EUR | 54億 EUR | 83.71億 EUR | 62.23億 EUR |
会社概要が更新されました 2026年10月14日.
直近の発表実績
直近の発表実績
この株式へのエクスポージャーを報告している上場投資信託です。
Avantis International Equity ETFAVDE4076.92万0.21%192.5億 USD0.23%$90.05+0.52%
Fidelity Enhanced International ETFFENI3545.96万0.31%114.7億 USD0.28%$39.79+0.40%
VanEck Pharmaceutical ETFPPH3365.67万3.19%10.45億 USD0.36%$109.23-1.33%
First Trust Value Line Dividend Index FundFVD3008.05万0.39%76.69億 USD0.62%$48.09+0.25%
Invesco International Dividend Achievers ETFPID2475.46万2.88%8.6億 USD0.53%$21.86+0.55%
Portfolio Building Block World Pharma and Biotech Index ETFPBPH1962.11万1.85%10.61億 USD0.13%$27.925-1.68%
GMO International Value ETFGMOI1541.99万2.40%6.55億 USD0.60%$39.55+0.97%
Brown Advisory Sustainable Value ETFBASV598.98万1.44%4.15億 USD0.71%$30.4895-0.36%Avantis International Equity ETFAVDEFidelity Enhanced International ETFFENIVanEck Pharmaceutical ETFPPHFirst Trust Value Line Dividend Index FundFVDInvesco International Dividend Achievers ETFPIDPortfolio Building Block World Pharma and Biotech Index ETFPBPHGMO International Value ETFGMOIBrown Advisory Sustainable Value ETFBASVAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
